Johnson & Johnson (NYSE:JNJ) Stock Purchased Rep. Lloyd Doggett

Posted by Grant Hamersma on Jul 8th, 2026

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on July 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on June 9th.

Representative Lloyd Doggett also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 6/18/2026.
Purchased $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 6/12/2026.
Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 6/10/2026.
Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 5/15/2026.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $267.35 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The stock has a market cap of $643.56 billion, a PE ratio of 30.91, a PEG ratio of 2.54 and a beta of 0.24. The company’s fifty day moving average is $235.09 and its 200 day moving average is $232.13. Johnson & Johnson has a 52 week low of $154.21 and a 52 week high of $269.43.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company’s revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Investors are buying JNJ ahead of earnings, helped by a higher company outlook, a recent analyst price-target increase, and expectations for another solid quarter. Johnson & Johnson (JNJ) Could Be 34% Below Fair Value Following IMAAVY Update
Positive Sentiment: Wall Street commentary says JNJ’s recent record run reflects rising price targets and strong institutional buying, reinforcing the bullish view on the stock. Johnson & Johnson (JNJ) Stock Surges Past Record High as Wall Street Raises Price Targets
Positive Sentiment: Analysts expect J&J to report higher second-quarter earnings, which is helping sentiment into the July 15 earnings release. Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Neutral Sentiment: Recent articles continue to frame Johnson & Johnson as a defensive healthcare name with dependable dividend income, which may support holding interest but is not a direct catalyst. Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Negative Sentiment: One market note highlighted unusual put option activity after JNJ’s runup, suggesting some traders are positioning for a pullback or near-term volatility. Unusual Put Option Activity in Johnson & Johnson After JNJ Stock’s Recent Runup

Analyst Ratings Changes

Several research firms recently issued reports on JNJ. Argus raised their price target on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Raymond James Financial increased their price objective on Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Daiwa Securities Group lifted their target price on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Finally, Barclays boosted their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $257.13.

Read Our Latest Report on Johnson & Johnson

Institutional Trading of Johnson & Johnson

Large investors have recently bought and sold shares of the company. Sierra Capital LLC raised its holdings in Johnson & Johnson by 0.5% in the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after purchasing an additional 41 shares in the last quarter. Beaird Harris Wealth Management LLC grew its position in shares of Johnson & Johnson by 1.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after buying an additional 42 shares during the period. Ballast Advisors LLC grew its position in shares of Johnson & Johnson by 1.2% in the 1st quarter. Ballast Advisors LLC now owns 3,598 shares of the company’s stock worth $879,000 after buying an additional 42 shares during the period. Broadleaf Partners LLC increased its stake in shares of Johnson & Johnson by 0.6% in the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock worth $1,521,000 after acquiring an additional 43 shares in the last quarter. Finally, Jessup Wealth Management Inc lifted its position in Johnson & Johnson by 0.6% during the 4th quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock valued at $1,567,000 after acquiring an additional 44 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas’ 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas’ 37th Congressional District. He declared candidacy for the 2026 election.

Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett’s career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.